P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions
Background It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.
F Gragnano, R Mehran, M Branca… - Journal of the …, 2023 - europepmc.org
Background It remains unclear whether P2Y 12 inhibitor monotherapy preserves ischemic
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions
Journal of the American College of Cardiology, 2023 - yonsei.elsevierpure.com
Background: It remains unclear whether P2Y 12 inhibitor monotherapy preserves ischemic
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
[HTML][HTML] P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions
F Gragnano, R Mehran, M Branca, A Franzone… - Journal of the American …, 2023 - Elsevier
Background It remains unclear whether P2Y 12 inhibitor monotherapy preserves ischemic
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions
F Gragnano, R Mehran, M Branca… - Journal of the …, 2023 - scholarworks.bwise.kr
Background: It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.
F Gragnano, R Mehran, M Branca… - Journal of the …, 2023 - boris.unibe.ch
BACKGROUND It remains unclear whether P2Y12 inhibitor monotherapy preserves
ischemic protection while limiting bleeding risk compared with dual antiplatelet therapy …
ischemic protection while limiting bleeding risk compared with dual antiplatelet therapy …
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions
F Gragnano, R Mehran, M Branca… - JOURNAL OF THE …, 2023 - iris.unicampania.it
Background: It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions
F Gragnano, R Mehran, M Branca… - Journal of the …, 2023 - pubmed.ncbi.nlm.nih.gov
Background It remains unclear whether P2Y 12 inhibitor monotherapy preserves ischemic
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …